A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects

Summary

This is 2-part study. The primary objective of Part 1 is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Type 2 Diabetes

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

AdipoPharma LLC

Last updated on ClinicalTrials.gov

September 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites